申请人:Chroma Therapeutics Ltd.
公开号:US08106091B2
公开(公告)日:2012-01-31
Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases:
wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is a radical of formula R-L1-Y1—(CH2)z—, wherein: z is 0 or 1; R is a radical of formula (X) or (Y)
R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R6 is hydrogen, or optionally substituted C1-C6 alkyl, C3-C7 cycloalkyl, aryl or heteroaryl or —(C═O)R3, —(C═O)OR3, or —(C═O)NR3 wherein R3 is hydrogen or optionally substituted (C1-C6)alkyl; Y1 is a bond, —(C═O)—, —S(O2)—, —C(═O)O—, —OC(═O)—, —(C═O)NR3—, —NR3(C═O)—, —S(O2)NR3—, —NR3S(O2)—, or —NR3(C═O)NR4—, wherein R3 and R4 are independently hydrogen or optionally substituted (C1-C6)alkyl, L1 is a divalent linker radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n, p, Q, Alk1 and Alk2 are as defined in the claims.
式为(IA)或(IB)的化合物是IkB激酶(IKK)活性的抑制剂,并可用于治疗自身免疫和炎症性疾病:其中R7是氢或可选取代的(C1-C6)烷基;环A是5-13环原子的可选取代芳基或杂芳基环;Z是公式R-L1-Y1—(CH2)z—的基团,其中:z为0或1;R是公式(X)或(Y)的基团,R1是羧酸基(—COOH),或者是可被一个或多个细胞内酯酶水解成羧酸基的酯基;R6是氢,或可选取代的C1-C6烷基,C3-C7环烷基,芳基或杂芳基或—(C═O)R3,—(C═O)OR3或—(C═O)NR3,其中R3是氢或可选取代的(C1-C6)烷基;Y1是键,—(C═O)—,—S(O2)—,—C(═O)O—,—OC(═O)—,—(C═O)NR3—,—NR3(C═O)—,—S(O2)NR3—,—NR3S(O2)—或—NR3(C═O)NR4—,其中R3和R4独立地是氢或可选取代的(C1-C6)烷基,L1是公式-(Alk1)m(Q)n(Alk2)p-的二价连接基团,其中m,n,p,Q,Alk1和Alk2如权利要求中所定义。